CD34⁺ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.

IF 1.9 4区医学 Q3 HEMATOLOGY

Transfusion Medicine and Hemotherapy Pub Date : 2023-08-23 eCollection Date: 2023-10-01 DOI:10.1159/000531799

Antti Samuli Turunen, Outi Kuittinen, Hanne Kuitunen, Kaija Vasala, Karri Penttilä, Minna Harmanen, Leena Keskinen, Pentti Mäntymaa, Jukka Pelkonen, Ville Varmavuo, Esa Jantunen, Anu Partanen

{"title":"CD34+ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.","authors":"Antti Samuli Turunen, Outi Kuittinen, Hanne Kuitunen, Kaija Vasala, Karri Penttilä, Minna Harmanen, Leena Keskinen, Pentti Mäntymaa, Jukka Pelkonen, Ville Varmavuo, Esa Jantunen, Anu Partanen","doi":"10.1159/000531799","DOIUrl":null,"url":null,"abstract":"Backgound: Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy.Study design and methods: This prospective multicenter study evaluated the impact of CD34+ cell mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery and outcome in 42 MCL patients.Results: During CD34+ cell mobilization, a higher blood CD34+ cell count (>30 × 106/L) was associated with improved overall survival (median not reached [NR] vs. 57 months, p = 0.04). The use of plerixafor did not impact outcome. Higher number of viable cryopreserved graft CD34+ cells (>3.0 × 106/kg) was associated with faster platelet (median 11 vs. 15 days, p = 0.03) and neutrophil (median 9 vs. 10 days, p = 0.02) recovery posttransplant. Very low graft CD3+CD8+ cell count (≤10 × 106/kg) correlated with worse progression-free survival (PFS) (HR 4.136, 95% CI 1.547-11.059, p = 0.005). On the other hand, higher absolute lymphocyte count >2.5 × 109/L at 30 days after ASCT (ALC-30) was linked with better PFS (median NR vs. 99 months, p = 0.045) and overall survival (median NR in either group, p = 0.05).Conclusions: Better mobilization capacity and higher graft CD3+CD8+ cell count had a positive prognostic impact in this study, in addition to earlier lymphocyte recovery (ALC-30>2.5 × 106/L). These results need to be validated in another study with a larger patient cohort.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601603/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine and Hemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000531799","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Backgound: Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy.

Study design and methods: This prospective multicenter study evaluated the impact of CD34⁺ cell mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery and outcome in 42 MCL patients.

Results: During CD34⁺ cell mobilization, a higher blood CD34⁺ cell count (>30 × 10⁶/L) was associated with improved overall survival (median not reached [NR] vs. 57 months, p = 0.04). The use of plerixafor did not impact outcome. Higher number of viable cryopreserved graft CD34⁺ cells (>3.0 × 10⁶/kg) was associated with faster platelet (median 11 vs. 15 days, p = 0.03) and neutrophil (median 9 vs. 10 days, p = 0.02) recovery posttransplant. Very low graft CD3⁺CD8⁺ cell count (≤10 × 10⁶/kg) correlated with worse progression-free survival (PFS) (HR 4.136, 95% CI 1.547-11.059, p = 0.005). On the other hand, higher absolute lymphocyte count >2.5 × 10⁹/L at 30 days after ASCT (ALC-30) was linked with better PFS (median NR vs. 99 months, p = 0.045) and overall survival (median NR in either group, p = 0.05).

Conclusions: Better mobilization capacity and higher graft CD3⁺CD8⁺ cell count had a positive prognostic impact in this study, in addition to earlier lymphocyte recovery (ALC-30>2.5 × 10⁶/L). These results need to be validated in another study with a larger patient cohort.

Abstract Image

查看原文本刊更多论文

CD34+细胞动员、自体移植物细胞组成和套细胞淋巴瘤患者的预后。

背景：自体干细胞移植（ASCT）是一线化学免疫治疗后符合移植条件的套细胞淋巴瘤（MCL）患者的标准治疗方法。研究设计和方法：这项前瞻性多中心研究评估了流式细胞术分析的CD34+细胞动员和移植物细胞组成对42名MCL患者血液学恢复和预后的影响。结果：在CD34+细胞动员过程中，较高的血液CD34+细胞计数（>30×106/L）与总生存率的提高有关（中位未达到[NR]，而57个月，p=0.04）。使用普利沙福不会影响结果。更高数量的活的冷冻保存移植物CD34+细胞（>3.0×106/kg）与移植后更快的血小板（中位数11天与15天，p=0.03）和中性粒细胞（中位数9天与10天，p=0.02）恢复有关。极低的移植物CD3+CD8+细胞计数（≤10×106/kg）与较差的无进展生存期（PFS）相关（HR 4.136，95%CI 1.547-11.059，p=0.005），ASCT（ALC-30）后30天，较高的绝对淋巴细胞计数>2.5×109/L与较好的PFS（中位NR vs.99个月，p=0.045）和总生存率（两组中位NR，p=0.05）有关。这些结果需要在另一项具有更大患者队列的研究中得到验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion Medicine and Hemotherapy 医学-免疫学

CiteScore

4.00

自引率

9.10%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal is devoted to all areas of transfusion medicine. These include the quality and security of blood products, therapy with blood components and plasma derivatives, transfusion-related questions in transplantation, stem cell manipulation, therapeutic and diagnostic problems of homeostasis, immuno-hematological investigations, and legal aspects of the production of blood products as well as hemotherapy. Both comprehensive reviews and primary publications that detail the newest work in transfusion medicine and hemotherapy promote the international exchange of knowledge within these disciplines. Consistent with this goal, continuing clinical education is also specifically addressed.